Upgrade to SI Premium - Free Trial

Form 3 Eloxx Pharmaceuticals, For: Jun 05 Filed by: Domicilium Real Estate Fund III LP

June 17, 2026 5:11 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Domicilium Real Estate Fund III LP

(Last) (First) (Middle)
535 S. KIMBALL AVE, SUITE 140

(Street)
SOUTHLAKE TX 76092

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/05/2026
3. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
common stock, $0.01 par value per share 14,285
I
See footnote (1)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Pre-funded Warrant (2) (2) common stock, $0.01 par value per share 238,422 0.11 I See footnote (3)
Pre-funded Warrant (2) (2) common stock, $0.01 par value per share 1,196,067 0.11 I See footnote (4)
Pre-funded Warrant (2) (2) common stock, $0.01 par value per share 361,578 0.11 I See footnote (5)
Pre-funded Warrant (2) (2) common stock, $0.01 par value per share 611,317 0.11 I See footnote (6)
Explanation of Responses:
1. The securities may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), and (ii) Daniel Simon, the managing member of Domicilium.
2. The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.
3. The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.
4. The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.
5. The securities are owned directly by MSEK Charleston LLC ("MSEK") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to MSEK, and (ii) Daniel Simon, the managing member of Domicilium.
6. The securities are owned directly by Bold Stroke Investments, LLC ("Bold Stroke") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to Bold Stroke, and (ii) Daniel Simon, the managing member of Domicilium.
Remarks:
Domicilium Capital Partners LLC, Domicilium Real Estate Fund III GP LLC, Daniel Simon, BKJLAGG, LLC, MSEK Charleston LLC and Bold Stroke Investments, LLC will be reported as a Reporting Person on a subsequent Form 3 once CIK codes are received.

Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 3 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Domicilium Real Estate Fund III LP, By: Domicilium Real Estate Fund III GP LLC, its General Partner, By: /s/ Daniel Simon, Managing Member 06/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings